EUVIMEDScopri EUVIMED
Crossref

A novel multi‐epitope peptide vaccine targeting immunogenic antigens of Ebola and monkeypox viruses with potential of immune responses provocation in silico

Shirin Mahmoodi iD, Javad Zamani Amirzakaria, Abdolmajid Ghasemian iD

Biotechnology and Applied Biochemistry · 2025

DOI: 10.1002/bab.2646 ↗

At a glance

Journal article in Biotechnology and Applied Biochemistry, 2025. Written by Shirin Mahmoodi and 2 co-authors. Institution: Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Fasa University of Medical Sciences, Fasa, Iran. Major MEDLINE topics: Ebolavirus, Vaccines, Subunit, Monkeypox virus, Antigens, Viral. 106 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

The emergence or reemergence of monkeypox (Mpox) and Ebola virus (EBOV) agents causing zoonotic diseases remains a huge threat to human health. Our study aimed at designing a multi‐epitope vaccine (MEV) candidate to target both the Mpox and EBOV agents using immunoinformatics tools. Viral protein sequences were retrieved, and potential nonallergenic, nontoxic, and antigenic epitopes were obtained. Next, cytotoxic and helper T‐cell (CTL and HTL, respectively) and B‐cell (BCL) epitopes were predicted, and those potential epitopes were fused utilizing proper linkers. The in silico cloning and expression processes were implemented using Escherichia coli K12. The immune responses were prognosticated using the C‐ImmSim server. The MEV construct (29.53 kDa) included four BCL, two CTL, and four HTL epitopes and adjuvant. The MEV traits were pertinent in terms of antigenicity, non‐allergenicity, nontoxicity, physicochemical characters, and stability. The MEV candidate was also highly expressed in E. coli K12. The strong affinity of MEV‐TLR3 was confirmed using molecular docking and molecular dynamics simulation analyses. Immune simulation analyses unraveled durable activation and responses of cellular and humoral arms alongside innate immune responses. The designed MEV candidate demonstrated appropriate traits and was promising in the prediction of immune responses against both Mpox and EBOV agents. Further experimental assessments of the MEV are required to verify its efficacy.

Subjects

MeSH terms (MEDLINE)

EbolavirusVaccines, SubunitMonkeypox virusAntigens, ViralComputer SimulationEpitopesViral VaccinesHumansMolecular Docking SimulationEpitopes, T-LymphocyteProtein Subunit Vaccines

Author keywords

Ebola virusMpox virusmulti‐epitope vaccinevaccinomic approach

Substances

Vaccines, SubunitAntigens, ViralEpitopes, T-LymphocyteEpitopesViral VaccinesProtein Subunit Vaccines

Authors and institutions

  • Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Fasa University of Medical Sciences, Fasa, Iran.
  • Department of Plant Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
  • Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.

ORCID profiles: Shirin Mahmoodi, Abdolmajid Ghasemian

Cite

APA

Mahmoodi, S., Amirzakaria, J. Z., & Ghasemian, A. (2025). A novel multi‐epitope peptide vaccine targeting immunogenic antigens of Ebola and monkeypox viruses with potential of immune responses provocation in silico. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.2646

Vancouver

Mahmoodi S, Amirzakaria JZ, Ghasemian A. A novel multi‐epitope peptide vaccine targeting immunogenic antigens of Ebola and monkeypox viruses with potential of immune responses provocation in silico. Biotechnology and Applied Biochemistry. 2025. doi:10.1002/bab.2646

BibTeX
@article{Mahmoodi2025,
  author = {Mahmoodi, Shirin and Amirzakaria, Javad Zamani and Ghasemian, Abdolmajid},
  title = {A novel multi‐epitope peptide vaccine targeting immunogenic antigens of Ebola and monkeypox viruses with potential of immune responses provocation in silico},
  journal = {Biotechnology and Applied Biochemistry},
  year = {2025},
  doi = {10.1002/bab.2646}
}
Start for free →